ThirtyFiveBio
Pre-clinicalApplying specialist knowledge to develop small molecule antagonists of genetically-validated GPCR GPR35.
Founded
2021
Focus
Small Molecules
About
Applying specialist knowledge to develop small molecule antagonists of genetically-validated GPCR GPR35.
Funding History
1Total raised: $4.5M
Seed$4.5MUndisclosedJun 15, 2023
Company Info
TypePrivate
Founded2021
LocationOxford, United Kingdom
StagePre-clinical
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile